Ask a Question
Genesis CX STM Series (End User)
Genesis CX STM Series (End User)
Genesis CX STM-Series (End User)

​High power CW lasers for life sciences application from 355 nm to 577 nm.

The Genesis CX STM-Series (End User) is a single transverse mode, TEMoo is intended for life sciences and research application, and is available at several wavelengths from 355 nm to 577 nm, with up to 10W of output power.

The Genesis CX STM-Series (End User) delivers extremely low noise, outstanding beam quality and pointing stability. The CX STM-Series (End User) is CDRH and CE-compliant and is designed for the end user with software and front panel interface. Air-cooled and water-cooled options are available.

General Specifications

Wavelength (nm)
Power (mW)
Genesis CX 355-40/60/80/100/150/200/250 STM
40, 60, 80, 100, 150, 200 and 250
Genesis CX 460-1000 STM (Preliminary)
Genesis CX 480-1000/2000 STM (Preliminary)
1000 and 2000
Genesis CX 488-2000/4000 STM (Preliminary)
2000 and 4000
Genesis CX 514-2000/4000 STM
2000 and 4000
Genesis CX 532-2000/5000/7000/8000/10000 STM
2000, 5000, 7000, 8000, and 10,000
Genesis CX 577-1000/2000/3000 STM (Preliminary)
1000, 2000 and 3000

Related Materials

Call 1-800-227-8840

Outside the U.S. 1-408-764-4983

Coherent has locations across the globe that are available to provide support for any product, service or inquiry.

Visit our Contact Page to connect with any of our global sites.

Corporate Headquarters
Coherent Inc.
5100 Patrick Henry Drive
Santa Clara, CA 95054 USA


Send Us a Message

Please Read Before Continuing

Risk factors: Except for the historical information contained here, many of the matters discussed in this Web site are forward-looking statements, based on expectations at the time they were made, that involve risks and uncertainties that could cause our results to differ materially from those expressed or implied by such statements. These risks are detailed in the “Factors That May Affect Future Results” section of our latest 10-K or 10-Q filing. Coherent assumes no obligation to update these forward-looking statements.

I have read the terms and conditions